It was estimated that as of 2022 around 24.4 million people in the United States had been diagnosed with diabetes. The number of people diagnosed with diabetes in the U.S. has increased in recent years and the disease is now a major health issue. Diabetes is now the eighth leading cause of death in the United States, accounting for three percent of all deaths.

What is prediabetes? A person is considered to have prediabetes if their blood sugar levels are higher than normal but not high enough to be diagnosed with type 2 diabetes. As of 2021, it was estimated that around 53 million men and 44 million women in the United States had prediabetes. However, according to the CDC, around 80 percent of these people do not know they have this condition. Not only does prediabetes increase the risk of developing type 2 diabetes, but also increases the risk of heart disease and stroke. The states with the highest share of adults who had ever been told they have prediabetes are Hawaii, California, and Alaska.

The prevalence of diabetes in the United States As of 2022, around 8.4 percent of adults in the United States had been diagnosed with diabetes, an increase from six percent in the year 2000. Diabetes is much more common among older adults, with almost a quarter of those aged 65 years and older diagnosed with diabetes, compared to just three percent of those aged 18 to 44 years. The states with the highest prevalence of diabetes among adults are Alabama, Mississippi, and West Virginia, while Colorado and Alaska report the lowest rates. In Alabama, around 17 percent of adults have been diagnosed with diabetes.

United States US: Diabetes Prevalence: % of Population Aged 20-79 data was reported at 10.790 % in 2017. United States US: Diabetes Prevalence: % of Population Aged 20-79 data is updated yearly, averaging 10.790 % from Dec 2017 (Median) to 2017, with 1 observations. United States US: Diabetes Prevalence: % of Population Aged 20-79 data remains active status in CEIC and is reported by World Bank. The data is categorized under Global Database’s USA – Table US.World Bank: Health Statistics. Diabetes prevalence refers to the percentage of people ages 20-79 who have type 1 or type 2 diabetes.; ; International Diabetes Federation, Diabetes Atlas.; Weighted average;

In 2022, the prevalence of diagnosed diabetes in the United States among people aged 18 and over amounted to 8.4 percent.

How many people in the United States have diabetes? It was estimated that in 2022, around 24.4 million people in the United States had been diagnosed with diabetes. The number of people living with diabetes has increased over the past few decades, with only five million people living with diabetes in the year 1980. Diabetes in the United States is more common among older adults with around 24 percent of those aged 65 years and older diagnosed with diabetes, compared to 15 percent of those aged 45 to 64 years.

Leading diabetic states

In 2021, the U.S. states with the highest prevalence of diagnosed diabetes were Alabama, Mississippi, and West Virginia, respectively. Just over 17 percent of adults in Alabama had diabetes that year. Roughly 14 percent of adults in Georgia had been diagnosed with diabetes before or during the measured period, putting the state of Georgia in tenth place.

In 2023, there were 22.4 deaths from diabetes mellitus per 100,000 people in the United States. The death rate caused by this condition has fluctuated over the past decades, reaching almost 26 deaths per 100,000 people in the early 2000s, and about 18 deaths in 1980. Prevalence of diabetes In 2022, around 8.4 percent of the adult population in the U.S. had diabetes. In total, around 38 million adults in the United States are currently living with diabetes. Of this total, the vast majority were aged 45 years and older. The states with the highest share of adults with diabetes are West Virginia, Mississippi, and Louisiana. Cure for diabetes? Researchers are helping diabetics put their Type 2 diabetes into remission, where the blood sugar levels are kept within a healthy range. For Type 1, scientists are looking for ways to prevent the immune system’s attack on beta cells, which causes diabetes. These cells, located in the pancreas, produce the insulin people need to live. As of yet, there is no cure for diabetes mellitus; however, scientists are researching ways to make diabetes harmless one day.

In 2023, West Virginia had the highest share of adults (18.2 percent) who had ever been told by a doctor that they had diabetes. This statistic represents the percentage of adults in the United States who had ever been diagnosed diabetes as of 2023, by state.

From 2017 to March 2020, the prevalence of diabetes was highest among those with lower incomes, with around 20 percent of those who earned 130 percent or less of the federal poverty level suffering from diabetes. This statistic shows the prevalence of diabetes in the U.S. from 2017 to March 2020, by family income relative to the federal poverty level (FPL).

This dataset contains information on the total proportion of adults diagnosed with diabetes, collected from the system of health-related telephone surveys, the Behavioral Risk Factor Surveillance System (BRFSS), conducted in more than 400,000 patients, from 50 states in the US, the District of Columbia and three US territories.

Health, United States is an annual report on trends in health statistics, find more information at http://www.cdc.gov/nchs/hus.htm.

Population-based county-level estimates for prevalence of DC were obtained from the Institute for Health Metrics and Evaluation (IHME) for the years 2004-2012 (16). DC prevalence rate was defined as the propor-tion of people within a county who had previously been diagnosed with diabetes (high fasting plasma glu-cose 126 mg/dL, hemoglobin A1c (HbA1c) of 6.5%, or diabetes diagnosis) but do not currently have high fasting plasma glucose or HbA1c for the period 2004-2012. DC prevalence estimates were calculated using a two-stage approach. The first stage used National Health and Nutrition Examination Survey (NHANES) data to predict high fasting plasma glucose (FPG) levels (≥126 mg/dL) and/or HbA1C levels (≥6.5% [48 mmol/mol]) based on self-reported demographic and behavioral characteristics (16). This model was then applied to Behavioral Risk Factor Surveillance System (BRFSS) data to impute high FPG and/or HbA1C status for each BRFSS respondent (16). The second stage used the imputed BRFSS data to fit a series of small area models, which were used to predict county-level prevalence of diabetes-related outcomes, including DC (16). The EQI was constructed for 2006-2010 for all US counties and is composed of five domains (air, water, built, land, and sociodemographic), each composed of variables to represent the environmental quality of that domain. Domain-specific EQIs were developed using principal components analysis (PCA) to reduce these variables within each domain while the overall EQI was constructed from a second PCA from these individual domains (L. C. Messer et al., 2014). To account for differences in environment across rural and urban counties, the overall and domain-specific EQIs were stratified by rural urban continuum codes (RUCCs) (U.S. Department of Agriculture, 2015). Results are reported as prevalence rate differences (PRD) with 95% confidence intervals (CIs) comparing the highest quintile/worst environmental quality to the lowest quintile/best environmental quality expo-sure metrics. PRDs are representative of the entire period of interest, 2004-2012. Due to availability of DC data and covariate data, not all counties were captured, however, the majority, 3134 of 3142 were utilized in the analysis. This dataset is not publicly accessible because: EPA cannot release personally identifiable information regarding living individuals, according to the Privacy Act and the Freedom of Information Act (FOIA). This dataset contains information about human research subjects. Because there is potential to identify individual participants and disclose personal information, either alone or in combination with other datasets, individual level data are not appropriate to post for public access. Restricted access may be granted to authorized persons by contacting the party listed. It can be accessed through the following means: Human health data are not available publicly. EQI data are available at: https://edg.epa.gov/data/Public/ORD/NHEERL/EQI. Format: Data are stored as csv files. This dataset is associated with the following publication: Jagai, J., A. Krajewski, K. Price, D. Lobdell, and R. Sargis. Diabetes control is associated with environmental quality in the USA. Endocrine Connections. BioScientifica Ltd., Bristol, UK, 10(9): 1018-1026, (2021).

This data package contains dataset on prevalence rates of health conditions and diseases like obesity, diabetes and hearing loss and health risk factors for diseases like tobacco, alcohol and drug use.

Population-based county-level estimates for diagnosed (DDP), undiagnosed (UDP), and total diabetes prevalence (TDP) were acquired from the Institute for Health Metrics and Evaluation (IHME) for the years 2004-2012 (Evaluation 2017). Prevalence estimates were calculated using a two-stage approach. The first stage used National Health and Nutrition Examination Survey (NHANES) data to predict high fasting plasma glucose (FPG) levels (≥126 mg/dL) and/or hemoglobin A1C (HbA1C) levels (≥6.5% [48 mmol/mol]) based on self-reported demographic and behavioral characteristics (Dwyer-Lindgren, Mackenbach et al. 2016). This model was then applied to Behavioral Risk Factor Surveillance System (BRFSS) data to impute high FPG and/or A1C status for each BRFSS respondent (Dwyer-Lindgren, Mackenbach et al. 2016). The second stage used the imputed BRFSS data to fit a series of small area models, which were used to predict the county-level prevalence of each of the diabetes-related outcomes (Dwyer-Lindgren, Mackenbach et al. 2016). Diagnosed diabetes was defined as the proportion of adults (age 20+ years) who reported a previous diabetes diagnosis, represented as an age-standardized prevalence percentage. Undiagnosed diabetes was defined as proportion of adults (age 20+ years) who have a high FPG or HbA1C but did not report a previous diagnosis of diabetes. Total diabetes was defined as the proportion of adults (age 20+ years) who reported a previous diabetes diagnosis and/or had a high FPG/HbA1C. The age-standardized diabetes prevalence (%) was used as the outcome. The EQI was constructed for 2000-2005 for all US counties and is composed of five domains (air, water, built, land, and sociodemographic), each composed of variables to represent the environmental quality of that _domain. Domain-specific EQIs were developed using principal components analysis (PCA) to reduce these variables within each _domain while the overall EQI was constructed from a second PCA from these individual domains (L. C. Messer et al., 2014). To account for differences in environment across rural and urban counties, the overall and _domain-specific EQIs were stratified by rural urban continuum codes (RUCCs) (U.S. Department of Agriculture, 2015). This dataset is not publicly accessible because: EPA cannot release personally identifiable information regarding living individuals, according to the Privacy Act and the Freedom of Information Act (FOIA). This dataset contains information about human research subjects. Because there is potential to identify individual participants and disclose personal information, either alone or in combination with other datasets, individual level data are not appropriate to post for public access. Restricted access may be granted to authorized persons by contacting the party listed. It can be accessed through the following means: Human health data are not available publicly. EQI data are available at: https://edg.epa.gov/data/Public/ORD/NHEERL/EQI. Format: Data are stored as csv files. This dataset is associated with the following publication: Jagai, J., A. Krajewski, S. Shaikh, D. Lobdell, and R. Sargis. Association between environmental quality and diabetes in the U.S.A.. Journal of Diabetes Investigation. John Wiley & Sons, Inc., Hoboken, NJ, USA, 11(2): 315-324, (2020).

The average for 2021 based on 20 countries was 8.73 percent. The highest value was in Mexico: 16.9 percent and the lowest value was in Ecuador: 4.4 percent. The indicator is available from 2000 to 2021. Below is a chart for all countries where data are available.

According to the data from January 2023, 12 percent of respondents said that rising health care costs were the most important health issue facing the United States. While COVID-19 and cancer each with 11 percent ranked second on the list. Health issues like alcoholism, stroke, and rare diseases were considered important issues by only one percent of respondents.

Issues with healthcare costs

Currently, the most urgent problem facing American healthcare is the high costs of care. The high expense of healthcare may deter people from getting the appropriate treatment when they need medical care or cause them to completely forego preventative care visits. Many Americans reported that they may skip prescription doses or refrain from taking medication as prescribed due to financial concerns. Such health-related behavior can result in major health problems, which may raise the long-term cost of care. Inflation, medical debt, and unforeseen medical expenses have all added to the burden that health costs are placing on household income.

Gun violence issue

The gun violence epidemic has plagued the United States over the past few years, yet very little has been done to address the issue. In recent years, gun violence has become the leading cause of death among American children and teens. By early May 2023, the U.S. has witnessed more than 200 mass shootings, the surge in the frequency of firearm attacks is alarming. Even though more than half of Americans are in favor of tougher gun control regulations, there is little political will to strongly reform the current gun law. Gun violence has a deep traumatic impact on survivors and society, it is developing into a major public health crisis in the United States.

Data for cities, communities, and City of Los Angeles Council Districts were generated using a small area estimation method which combined the survey data with population benchmark data (2022 population estimates for Los Angeles County) and neighborhood characteristics data (e.g., U.S. Census Bureau, 2017-2021 American Community Survey 5-Year Estimates). This indicator is based on self-report of ever being diagnosed with diabetes (type 1 or 2).Diabetes is associated with decreased life expectancy, heart disease and stroke, lower limb amputations, kidney disease, and blindness. It is also closely linked with obesity. Cities and communities can help prevent diabetes by adopting policies that support healthy food retail and physical activity and improve access to preventive care services.For more information about the Community Health Profiles Data Initiative, please see the initiative homepage.

Snapshot img

Type 2 Diabetes Market Size 2025-2029

The type 2 diabetes market size is forecast to increase by USD 53.8 billion at a CAGR of 12.2% between 2024 and 2029.

The market is experiencing significant growth due to several key factors. The rising prevalence of diabetes, driven by unhealthy lifestyles and an aging population, is a major growth driver. Additionally, the low diagnosis rate presents an opportunity for market expansion. It is administered via different routes, including subcutaneous injection, insulin pumps, and insulin pens. According to the American Diabetes Association, approximately 26.8 million people in the United States have diabetes, and 7.3 million are undiagnosed. With increasing awareness and advancements in diagnostic tools, this number is expected to increase. These include continuous glucose monitoring systems, closed-loop insulin delivery systems, and non-pharmacological interventions such as diet and exercise. Furthermore, the growing burden of diabetes on healthcare systems and the need for effective management solutions are creating new opportunities for market participants. Overall, the market is poised for growth in the coming years, driven by these key trends and challenges.

What will be the Size of the Type 2 Diabetes Market During the Forecast Period?

Request Free Sample

The market encompasses a range of therapeutic compounds designed to manage and mitigate the effects of this chronic condition. With a global prevalence estimated to affect over 463 million people, primarily adolescents and young adults, the market exhibits significant growth due to the increasing burden of cardiovascular diseases, renal problems, and neurological complications associated with hyperglycemia. These complications include heart diseases, damage to the kidneys, and eye disorders, among others. Insulin and non-insulin medications, such as Jardiance, Tanzeum, and Trulicity, are commonly used to regulate blood sugar levels and alleviate symptoms like increased thirst, urination, fatigue, blurred vision, slow-healing wounds, and infections. Additionally, patients may experience tingling, numbness in feet and hands, and other neurological issues. Pharmaceutical companies continue to invest in research and development to address the unmet needs of this patient population and improve overall quality of life.

How is this Type 2 Diabetes Industry segmented and which is the largest segment?

The type 2 diabetes industry research report provides comprehensive data (region-wise segment analysis), with forecasts and estimates in 'USD billion' for the period 2025-2029, as well as historical data from 2019-2023 for the following segments.

Drug Class

  Insulin
  DPP-4 inhibitor
  GLP-1 receptor agonists
  SGLT-2 inhibitors
  Others


Distribution Channel

  Retail pharmacies
  Hospital pharmacies
  Online pharmacies


Delivery Mode

  Oral
  Injectable
  Continuous glucose monitoring (CGM)


Geography

  North America

    Canada
    US


  Europe

    Germany
    UK
    France
    Italy


  Asia

    China
    India
    Japan
    South Korea


  Rest of World (ROW)

By Drug Class Insights

The insulin segment is estimated to witness significant growth during the forecast period.

Type 2 diabetes is a chronic metabolic disorder characterized by insulin resistance and high blood glucose levels. This condition affects adolescents, teenagers, and young adults, leading to increased thirst, urination, fatigue, blurred vision, slow-healing wounds, infections, tingling, numbness in feet and hands, yeast infections, darkened skin areas, and neurological problems. Over time, high blood glucose levels can lead to cardiovascular diseases, renal problems, and damage to the eyes. Insulin, a peptide hormone, plays a crucial role in regulating blood glucose levels. It interacts with insulin receptors on cell surfaces, facilitating the absorption of glucose into the cells. Insulin deficiency or insulin resistance leads to hyperglycemia, which can result in complications. The market for therapeutic compounds to manage Type 2 diabetes includes various drug classes such as insulin, thiazolidinediones, PPAR receptors agonists, Dipeptidyl Peptidase-4 Inhibitors, Alpha-Glucosidase Inhibitors, Sulfonylureas, Secretagogues, Biguanides, and others.

Moreover, these medications help improve glycemic control, reduce cardiovascular risk, and avoid hypoglycemia. Insulin is available in various forms, including human insulin, analog insulins, and inhaled insulin. Retail pharmacies and online pharmacies offer convenience for patients to access insulin and other diabetes medications. The market for Type 2 diabetes medications is expected to grow significantly due to the increasing prevalence of the disease and the need for effective disease management. Emerging economies are expected to offer significant growth opportunities due to increasin

As of 2021, there were an estimated five million women in the United States with diabetes who had not yet been diagnosed. All together, there were some 29.4 million adults in the United States who had been diagnosed with diabetes as of that time. This statistic shows the estimated number of adults with diabetes in the United States as of 2021, by gender.

The prevalence of undiagnosed diabetes (% with 95% confidence intervals), by age, sex and site, with standardised prevalence and morbidity ratios.

United States US: Mortality from CVD, Cancer, Diabetes or CRD between Exact Ages 30 and 70: Male data was reported at 17.500 NA in 2016. This records an increase from the previous number of 17.200 NA for 2015. United States US: Mortality from CVD, Cancer, Diabetes or CRD between Exact Ages 30 and 70: Male data is updated yearly, averaging 17.500 NA from Dec 2000 (Median) to 2016, with 5 observations. The data reached an all-time high of 21.600 NA in 2000 and a record low of 17.200 NA in 2015. United States US: Mortality from CVD, Cancer, Diabetes or CRD between Exact Ages 30 and 70: Male data remains active status in CEIC and is reported by World Bank. The data is categorized under Global Database’s United States – Table US.World Bank.WDI: Health Statistics. Mortality from CVD, cancer, diabetes or CRD is the percent of 30-year-old-people who would die before their 70th birthday from any of cardiovascular disease, cancer, diabetes, or chronic respiratory disease, assuming that s/he would experience current mortality rates at every age and s/he would not die from any other cause of death (e.g., injuries or HIV/AIDS).; ; World Health Organization, Global Health Observatory Data Repository (http://apps.who.int/ghodata/).; Weighted average;

This forecast represents the disease prevalence of diabetes type 2 in the United States from 2007 to 2020. In 2020, the prevalence for type 2 diabetes will amount to 10.8 percent among the adult population in the United States.

The crude prevalence rate of diabetes is defined as the ratio of respondents that are 18 years or older who have ever been told by a health professional that they had diabetes (other than during pregnancy) over the total number of respondents in the study (excluding those who refused to answer, had a missing answer, or answered “don’t know/not sure”).Prevalence data are derived from Behavioral Risk Factor Surveillance System (BRFSS) (numerator) and population estimates from the U.S. Census Bureau (denominator).The 500 Cities Project seeks to provide city- and census tract-level small area estimates for chronic disease risk factors, health outcomes, and clinical preventive service use for the largest 500 cities in the United States.Data source: CDC (Division of Population Health, National Center for Chronic Disease Prevention and Health Promotion)Date: 2015